GRANISETRON

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Details

Stereochemistry	ACHIRAL
Molecular Formula	C18H24N4O
Molecular Weight	312.4094
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of GRANISETRON

Structure Search

SMILES

CN1N=C(C(=O)N[C@@H]2C[C@@H]3CCC[C@H](C2)N3C)C4=CC=CC=C14

InChI

InChIKey=MFWNKCLOYSRHCJ-BTTYYORXSA-N

InChI=1S/C18H24N4O/c1-21-13-6-5-7-14(21)11-12(10-13)19-18(23)17-15-8-3-4-9-16(15)22(2)20-17/h3-4,8-9,12-14H,5-7,10-11H2,1-2H3,(H,19,23)/t12-,13+,14-

HIDE SMILES / InChI

Molecular Formula	C18H24N4O
Molecular Weight	312.4094
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	3 / 3
E/Z Centers	0
Optical Activity	UNSPECIFIED

Approval Year

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:55:10 UTC 2023` Edited by `admin` on `Fri Dec 15 15:55:10 UTC 2023`
Record UNII	WZG3J2MCOL
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

GRANISETRON

Official Name

English

GRANISETRON [USAN]

Common Name

English

GRANISETRON [JAN]

Common Name

English

APF530

Code

English

LY-278584

Code

English

GRANISETRON [VANDF]

Common Name

English

GRANISETRON [USP MONOGRAPH]

Common Name

English

GRANISETRON [USP-RS]

Common Name

English

APF-530

Code

English

Granisetron [WHO-DD]

Common Name

English

1H-INDAZOLE-3-CARBOXAMIDE, 1-METHYL-N-(9-METHYL-9-AZABICYCLO(3.3.1)NON-3-YL)-, ENDO-

Common Name

English

GRANISETRON [MI]

Common Name

English

BRL-43694

Code

English

GRANISETRON [ORANGE BOOK]

Common Name

English

BRL 43694

Code

English

granisetron [INN]

Common Name

English

SANCUSO

Brand Name

English

1-Methyl-N-(9-methyl-endo-9-azabicyclo[3.3.1]non-3-yl)-1H-indazole-3-carboxamide

Common Name

English

SUSTOL

Brand Name

English

Classification Tree Code System Code

NCI_THESAURUS

C94726

Created by admin on Fri Dec 15 15:55:10 UTC 2023 , Edited by admin on Fri Dec 15 15:55:10 UTC 2023

NCI_THESAURUS

C267

Created by admin on Fri Dec 15 15:55:10 UTC 2023 , Edited by admin on Fri Dec 15 15:55:10 UTC 2023

NDF-RT

N0000175817

Created by admin on Fri Dec 15 15:55:10 UTC 2023 , Edited by admin on Fri Dec 15 15:55:10 UTC 2023

WHO-VATC

QA04AA02

Created by admin on Fri Dec 15 15:55:10 UTC 2023 , Edited by admin on Fri Dec 15 15:55:10 UTC 2023

LIVERTOX

467

Created by admin on Fri Dec 15 15:55:10 UTC 2023 , Edited by admin on Fri Dec 15 15:55:10 UTC 2023

WHO-ATC

A04AA02

Created by admin on Fri Dec 15 15:55:10 UTC 2023 , Edited by admin on Fri Dec 15 15:55:10 UTC 2023

NDF-RT

N0000175818

Created by admin on Fri Dec 15 15:55:10 UTC 2023 , Edited by admin on Fri Dec 15 15:55:10 UTC 2023

EMA ASSESSMENT REPORTS

SANCUSO (AUTHORIZED: VOMITTING)

Created by admin on Fri Dec 15 15:55:10 UTC 2023 , Edited by admin on Fri Dec 15 15:55:10 UTC 2023

Code System Code Type Description

INN

6230

Created by admin on Fri Dec 15 15:55:10 UTC 2023 , Edited by admin on Fri Dec 15 15:55:10 UTC 2023

PRIMARY

DRUG BANK

DB00889

Created by admin on Fri Dec 15 15:55:10 UTC 2023 , Edited by admin on Fri Dec 15 15:55:10 UTC 2023

PRIMARY

MERCK INDEX

m5842

Created by admin on Fri Dec 15 15:55:10 UTC 2023 , Edited by admin on Fri Dec 15 15:55:10 UTC 2023

PRIMARY

Merck Index

CAS

109889-09-0

Created by admin on Fri Dec 15 15:55:10 UTC 2023 , Edited by admin on Fri Dec 15 15:55:10 UTC 2023

PRIMARY

EPA CompTox

DTXSID0023111

Created by admin on Fri Dec 15 15:55:10 UTC 2023 , Edited by admin on Fri Dec 15 15:55:10 UTC 2023

PRIMARY

DAILYMED

WZG3J2MCOL

Created by admin on Fri Dec 15 15:55:10 UTC 2023 , Edited by admin on Fri Dec 15 15:55:10 UTC 2023

PRIMARY

ChEMBL

CHEMBL289469

Created by admin on Fri Dec 15 15:55:10 UTC 2023 , Edited by admin on Fri Dec 15 15:55:10 UTC 2023

PRIMARY

USAN

DD-30

Created by admin on Fri Dec 15 15:55:10 UTC 2023 , Edited by admin on Fri Dec 15 15:55:10 UTC 2023

PRIMARY

IUPHAR

2300

Created by admin on Fri Dec 15 15:55:10 UTC 2023 , Edited by admin on Fri Dec 15 15:55:10 UTC 2023

PRIMARY

SMS_ID

100000084258

Created by admin on Fri Dec 15 15:55:10 UTC 2023 , Edited by admin on Fri Dec 15 15:55:10 UTC 2023

PRIMARY

MESH

D017829

Created by admin on Fri Dec 15 15:55:10 UTC 2023 , Edited by admin on Fri Dec 15 15:55:10 UTC 2023

PRIMARY

NCI_THESAURUS

C62031

Created by admin on Fri Dec 15 15:55:10 UTC 2023 , Edited by admin on Fri Dec 15 15:55:10 UTC 2023

PRIMARY

CAS

124998-65-8

Created by admin on Fri Dec 15 15:55:10 UTC 2023 , Edited by admin on Fri Dec 15 15:55:10 UTC 2023

NON-SPECIFIC STEREOCHEMISTRY

WIKIPEDIA

GRANISETRON

Created by admin on Fri Dec 15 15:55:10 UTC 2023 , Edited by admin on Fri Dec 15 15:55:10 UTC 2023

PRIMARY

FDA UNII

WZG3J2MCOL

Created by admin on Fri Dec 15 15:55:10 UTC 2023 , Edited by admin on Fri Dec 15 15:55:10 UTC 2023

PRIMARY

RS_ITEM_NUM

1298092

Created by admin on Fri Dec 15 15:55:10 UTC 2023 , Edited by admin on Fri Dec 15 15:55:10 UTC 2023

PRIMARY

EVMPD

SUB07964MIG

Created by admin on Fri Dec 15 15:55:10 UTC 2023 , Edited by admin on Fri Dec 15 15:55:10 UTC 2023

PRIMARY

CHEBI

5537

Created by admin on Fri Dec 15 15:55:10 UTC 2023 , Edited by admin on Fri Dec 15 15:55:10 UTC 2023

PRIMARY

DRUG CENTRAL

1329

Created by admin on Fri Dec 15 15:55:10 UTC 2023 , Edited by admin on Fri Dec 15 15:55:10 UTC 2023

PRIMARY

RXCUI

26237

Created by admin on Fri Dec 15 15:55:10 UTC 2023 , Edited by admin on Fri Dec 15 15:55:10 UTC 2023

PRIMARY

RxNorm

Related Record Type Details


					318F6L70J8

GRANISETRON HYDROCHLORIDE

SALT/SOLVATE -> PARENT


					3X5G9S4YNB

GRANISETRON H-3

LABELED -> NON-LABELED

Amount:


					6D53G0FD0Z

PLASMA PROTEIN FRACTION (HUMAN)

BINDER->LIGAND

Interaction Type:

BINDING

Amount:


					WZG3J2MCOL

EXCRETED UNCHANGED

Comments:

Based on a study with intravenous injection, approximately 12% of the dose is excreted unchanged in the urine of healthy subjects in 48 hours.

Interaction Type:

AMOUNT EXCRETED

Qualification:

URINE

Amount:


					EA9HO2Z7V5

5-HYDROXYTRYPTAMINE RECEPTOR 3A

TARGET -> INHIBITOR

Qualification:

IC50

Amount:

Related Record Type Details


					GG8LX5R3UF

7-HYDROXYGRANISETRON

METABOLITE ACTIVE -> PARENT

Comments:

After both oral and intravenous administration, the metabolite is present at about 10% of that of the parent (Clarke et al., 1994; Boppana, 1995). Assuming similar free fractions, it can be estimated that the metabolite would contribute about 20% of the activity of the parent.

Amount:

Related Record Type Details


					F9P5J2E2BU

3-CARBOXY-1-METHYLINDAZOLE

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

USP

Amount:


					KC8X636ZZE

1-DESMETHYL GRANISETRON

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

USP

Amount:


					9JZ8WLY99W

9-DESMETHYL GRANISETRON

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

USP

Amount:


					OW447MGE8N

2-METHYL-N-(9-METHYL-9-AZABICYCLO(3.3.1)NON-3-YL)-,2H-INDAZOLE-3-CARBOXAMIDE, ENDO-

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

USP

Amount:

Related Record Type Details


					WZG3J2MCOL

ACTIVE MOIETY

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
Biological Half-life	PHARMACOKINETIC

Volume of Distribution	PHARMACOKINETIC

Tmax	PHARMACOKINETIC				following patch application